Changing Epidemiology of Bacterial Meningitis in the United States
|
|
- Brandon Shaw
- 6 years ago
- Views:
Transcription
1 Changing Epidemiology of Bacterial Meningitis in the United States William R. Short, MD and Allan R. Tunkel, MD, PhD Address Department of Medicine, Medical College of Pennsylvania/Hahnemann University, 3300 Henry Avenue, Philadelphia, PA 19129, USA. Current Infectious Disease Reports 2000, 2: Current Science Inc. ISSN Copyright 2000 by Current Science Inc. Bacterial meningitis is an important cause of morbidity and mortality in the United States and throughout the world. Over the past 20 years, there have been significant changes in the epidemiology of bacterial meningitis. The most important change is the decrease in the frequency of Haemophilus influenzae type b as the most common etiologic agent of bacterial meningitis, since the H. influenzae type b conjugate vaccine was introduced. Streptococcccus pneumoniae is now the major cause of bacterial meningitis in the US and bacterial meningitis is now a disease predominantly of adults, rather than of infants and children. Emergence of antimicrobial resistance in S. pneumoniae has also altered the approach to antimicrobial therapy in patients with pneumococcal meningitis, indicating the need to use preventive strategies to reduce the frequency of this serious infection. Recent licensure of the heptavalent pneumococcal conjugate vaccine will likely decrease the overall incidence of pneumococcal meningitis. Introduction Recognition of the epidemiologic changes that have recently occurred in bacterial meningitis in the United States is essential for appropriate patient management. Here, we will highlight recent epidemiologic changes in the frequency of isolation of various meningeal pathogens since the introduction of the Haemophilus influenzae type b conjugate vaccine, detail the emergence of antimicrobial resistance in Streptococcus pneumoniae, and review expected epidemiologic trends. Familiarity with these changes is critical to providing optimal antimicrobial therapy and enacting the public health measures that are necessary to decrease the morbidity and mortality associated with this disease. Etiologic Agents Early studies of the epidemiology of bacterial meningitis in the 1950s, 1960s, and 1970s were retrospective, community-based, and conducted in relatively small patient populations [1 3]; as such, they did not accurately define the attack rates of bacterial meningitis in the US. In the late 1970s, the Centers for Disease Control (CDC), in collaboration with the Conference of State and Territorial Epidemiologists, acted on the need to determine optimally the trends associated with the etiologic agents of bacterial meningitis. The result was a nationwide surveillance system to gather prospective information concerning the incidence, risk factors, and causative agents of bacterial meningitis in the US. Since the system was implemented, three studies describing the epidemiologic changes in bacterial meningitis in the US over the past 20 years (Table 1) have yielded important public health information about this disorder. The first study examined the epidemiology of 13,974 cases of bacterial meningitis from 27 US states from 1978 through 1981 [4]. H. influenzae was the most common etiologic agent, accounting for 48.3% of cases, followed by Neisseria meningitidis (19.6%), and S. pneumoniae (13.3%). The overall attack rate (approximately 3.0 cases per 100,000 population) of bacterial meningitis did not change significantly during the study period, although there was variability based on gender, race, and age. The attack rates were higher among male patients than female patients (3.3 versus 2.6 cases per 100,000 population); among blacks than whites and Hispanics; and among children younger than 1 year of age particularly among neonates (younger than 1 month of age) than older victims. Among children younger than 1 year, group B streptococci were the most commonly isolated bacteria, followed by gram-negative enteric bacilli, Listeria monocytogenes, H. influenzae, S. pneumoniae, and N. meningitidis. Attack rates also rose among patients older than 60 years of age, with S. pneumoniae the most common pathogen isolated, followed by gram-negative bacilli and other microorganisms (ie, H. influenzae, N. meningitidis, group B streptococcus, and L. monocytogenes). This study indicated bacterial meningitis to be predominantly a disease of the very young and the elderly. However, the study had a major drawback, in that it used a voluntary reporting system; only 30% to 40% of cases were reported during the study period. In 1986, the local health departments of 5 states Missouri, New Jersey, Oklahoma, Tennessee, and Washington and Los Angeles county collaborated with the CDC in a laboratory-based surveillance study. The study focused on all
2 328 CNS and Eye Infections Table 1. Frequency of isolation of the 5 major meningeal pathogens in patients with bacterial meningitis in the US Microorganism Percentage of total cases Haemophilus influenzae Neisseria meningitidis Streptococcus pneumoniae Streptococcus agalactiae Listeria monocytogenes Data from Schonian et al. [4]; Woodruff [5]; and Cardosa et al. [13 ] cases of bacterial meningitis caused by the five most common meningeal pathogens, H. influenzae, S. pneumoniae, N. meningitidis, group B streptococcus, and L. monocytogenes). From a population of almost 34 million persons, 2158 cases were reported [5]. Because the study used laboratorybased surveillance rather than voluntary reporting, the overall incidence of bacterial meningitis was 2 to 3 times higher than that of the previous report. H. influenzae was again the most common etiologic agent identified (45% of cases), followed by S. pneumoniae (18%) and N. meningitidis (14%). Group B streptococcus remained the most common etiologic agent of bacterial meningitis in children younger than 1 month of age. There was little change in the frequency of isolation of the major meningeal pathogens in patients with bacterial meningitis in this study. Based on this finding, preventive strategies using vaccines were aggressively pursued. Prior to 1990, vaccination against invasive H. influenzae type b was based on the generation of an immune response against the capsular polysaccharide of the organism, which induced protective responses in older children and adults, but was did not induce an immune response in neonates. In December 1987 a H. influenzae type b conjugate vaccine was introduced; it induces immune responses in young infants by converting the organism s polysaccharide into a T cell-dependent antigen [6,7 ]. In October 1990, after its efficacy was demonstrated in a prospective study of more than 60,000 infants who received doses at 2, 4, and 6 months of age, the Food and Drug Administration (FDA) approved this vaccine for use [8]. Three H. influenzae type b conjugate vaccines are currently approved for clinical use. The American Academy of Pediatrics currently recommends universal immunization of infants with one of the licensed conjugate vaccines beginning at 2 months of age [9]. Since introduction of the conjugate vaccines, the number of cases of H. influenzae type b meningitis has decreased more than 90% throughout the world [10 12]. A follow-up laboratory-based surveillance study of bacterial meningitis cases was performed in the US 5 years after the approval of the H. influenzae type b conjugate vaccine [13 ]. It reviewed 248 cases of meningitis in 22 counties of 4 states Georgia, Tennessee, Maryland, and California with a total population of more than 10 million persons. In it, the most common cause of bacterial meningitis was S. pneumoniae (47% of cases), followed by N. meningitidis (25%), group B streptococcus (12%), L. monocytogenes (8%), and H. influenzae (7%). The incidence of bacterial meningitis caused by H. influenzae declined substantially, from 2.9 cases per 100,000 population in 1986 [5] to 0.2 cases per 100,000 population in 1995 [13 ], with little or no change in the incidence of bacterial meningitis caused by the other major meningeal pathogens. The median age of patients with bacterial meningitis was 25 years, versus a median age of 15 months prior to the introduction of the H. influenzae type b conjugate vaccine, which now makes bacterial meningitis primarily a disease of adults, in the US. Microorganism-specific case fatality rates were generally similar to those in the previous studies, with some decrease in mortality in patients with meningitis caused by S. agalactiae and L. monocytogenes (Table 2). The frequency of isolation of various etiologic agents of bacterial meningitis also varied according to patient age [13 ]. Among neonates, group B streptococcus was the most common cause of meningitis (70% of cases), followed by Escherichia coli; L. monocytogenes was isolated in about 20% of patients. In the group aged 1 to 23 months, S. pneumoniae (45% of cases) and N. meningitidis (31%) were the leading causes. In persons aged 2 to 18 years, N. meningitidis was most frequently isolated (59% of cases). In adults older than 18 years, S. pneumoniae accounted for the majority (62%) of the cases of bacterial meningitis. In persons age 60 and older, S. pneumoniae once again was the most common etiologic agent of bacterial meningitis, followed by L. monocytogenes. Antimicrobial Resistance in S. pneumoniae An important change in the epidemiology of bacterial meningitis has been the emergence of antimicrobial resistance in S. pneumoniae [14 ]. Penicillin resistance in S. pneumoniae was first experimentally induced in mice in 1943, although it was not until 1967 that the first penicillin-resistant isolate was identified, in a patient with hypogammaglobulinemia and brochiectasis. Penicillin resistance results from multiple
3 Changing Epidemiology of Bacterial Meningitis in the United States Short and Tunkel 329 Table 2. Case fatality rates of bacterial meningitis in the US, based on the isolated microorganism Microogranism Percentage of Total Cases Streptococcus pneumoniae Haemophilus influenzae Neisseria meningitidis Streptococcus agalactiae Listeria monocytogenes Data from Schonian et al. [4]; Woodruff [5]; and Cardosa et al. [13 ] Table 3. Minimal inhibitory concentration (MIC) breakpoints for antimicrobial agents used to treat pneumococcal meningitis Antimicrobial Agent MIC (?g/ml) Susceptible Intermediate Resistant Penicillin G < >2.0 Cefotaxime or ceftriaxone <0.5 1 >2.0 Chloramphenicol <4.0 - >8.0 Trimethoprim-sulfamethoxazole <0.5/9.5 1/19-2/38 >4/76 Adapted from Akhtar et al. [14 ] alterations of several of the penicillin-binding proteins, which are chromosomally mediated but do not cause any loss or gain of pneumococcal virulence. Recommendations of the National Committee on Clinical Laboratory Standards on the minimal inhibitory concentration (MIC) breakpoints determining pneumococcal susceptibility to various antimicrobial agents are found in Table 3 [14 ]. Risk factors for infection with drug-resistant S. pneumoniae include patient age extremes (especially younger than 6 years), recent antimicrobial therapy, coexisting illness or underlying disease, human immunodeficiency virus [HIV] infection, other immunodeficiencies, day-care center environment, recent or current hospitalization, and institutionalization (eg, nursing home, prison). Since the initial report of penicillin resistance in 1967, the incidence of antimicrobial resistance in pneumococci has increased throughout the world; recent studies have documented the frequency of penicillin-resistant pneumococci to be 41% in Southeast Asia [15], 13% in Brazil [16], and 56% in Taiwan [17]. Antimicrobial resistance has also been increasing in the US. In a study recently performed in Atlanta, 25% of pneumococcal isolates were resistant to penicillin (7% were highly resistant) [18 ]. Further, 26% were resistant to trimethoprim-sulfamethoxazole; 15% to erythromycin; 9% to cefotaxime; and 25% to multiple antimicrobial agents. The incidence of invasive pneumococcal infection was 30 cases per 100,000 population in this study. Trends indicating increasing antimicrobial resistance in pneumococci have made an impact on the approach to antimicrobial therapy in bacterial meningitis. Anecdotal reports have described cases of meningitis caused by pneumococcal strains resistant to penicillin or third-generation cephalosporins and the clinical failure of therapy using those drugs [19]. This has led to recommendations for combination therapy with vancomycin plus a third-generation cephalosporin (either cefotaxime or ceftriaxone), pending susceptibility testing [20 ]. Continued surveillance of antimicrobial resistance patterns is critical to make recommendations for antimicrobial therapy in patients with pneumococcal meningitis. Future Trends Following the dramatic success of the H. influenzae type b conjugate vaccine in prevention of invasive Haemophilus disease, the development of effective vaccines against the other meningeal pathogens might also be expected to further decrease the incidence of this devastating infection. Use of the pneumococcal vaccine (Pneumovax; Merck Frosst, Kirkland, Quebec, Canada) is currently recommended for the prevention of bacteremic pneumococcal disease in a select group of high-risk persons [21]. Highrisk factors include age 65 years or more; age 2 to 64 years combined with chronic cardiovascular disease; chronic pulmonary disease; diabetes mellitus; alcoholism; chronic liver disease; cerebrospinal fluid leaks; and functional or anatomic asplenia. Also at high risk are persons who are variously immunocompromised (ie, those with HIV infection, hematologic or generalized malignancies, chronic renal failure or nephrotic syndrome; those receiving immunosuppressive therapy; and those who have received an organ or bone marrow transplant). The vaccine is composed of capsular polysaccharide from 23 serotypes of
4 330 CNS and Eye Infections S. pneumoniae, which account for approximately 85% to 90% of the bacteremic infections; however, this vaccine is not immunogenic in infants. A recently-developed heptavalent pneumococcal conjugate (ie, serotypes 4, 6B, 9V, 14, 18C, 19F, 23F) vaccine uses a carrier protein composed of a non-toxic mutant diphtheria toxin, CRM197. In an initial study, the safety and immunogenicity of the vaccine were evaluated in 212 healthy 2-month-old infants who were equally randomized to receive 4 doses of either the heptavalent pneumococcal conjugate vaccine (PNCRM7) or an investigational meningococcal group C conjugate vaccine, which was used as the control [22]. The study demonstrated that there are fewer local reactions among patients who received PNCRM7 than among patients in the control group, although mild fever was commonly associated with both vaccines. All 7 serotypes were immunogenic, although the concentration of pneumococcal antibodies decreased in patients from around 7 months of age to 12 to 15 months of age. However, after a subsequent dose of the vaccine, the concentration of pneumococcal antibodies rose to a higher level than was previously obtained with vaccine administration at 2, 4, and 6 months of age. A large multicenter study of safety and efficacy was then conducted at Northern California Kaiser Permanente in Oakland, CA. This controlled, double-blind trial enrolled approximately 38,000 children, half of whom received the pneumococcal 7-valent conjugate vaccine, given at 2, 4, 6, and 12 to 15 months of age [23 ]. The vaccine was 97.4% effective in preventing invasive pneumococcal disease (including meningitis) caused by the 7 strains of pneumococcus in the vaccine, and 93.9% effective in preventing invasive disease caused by all pneumococcal serotypes. On February 17, 2000, the FDA approved the pneumococcal 7-valent conjugate vaccine (Prevnar; Wyeth-Ayerst, Radnor, PA) for the prevention of invasive pneumococcal disease. It is approved for all infants to the age of 23 months of age, as a series of inoculations administered at 2, 4, 6, and months of age [24]. The vaccine is not indicated for use in adults or as a substitute for other approved pneumococcal polysaccharide vaccines for highrisk children older than 2 years. A recent study anaylzed the cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children, hypothesizing a US birth cohort of 3.8 million infants [25 ]. It was estimated that vaccination would prevent more than 12,000 cases of meningitis and bacteremia, as well as 116 deaths due to pneumococcal infection for each US birth cohort. Thus, pneumococcal conjugate vaccination has the potential to be cost-effective relative to other preventive health strategies. At the manufacturer s list price of $58 per dose, infant vaccination would cost society $80,000 per life-year saved for all pneumococcal infections (a cost of $280,000 for use against meningitis). It is interesting to use these hypothetical data to project the likely benefits of vaccination. However, subsequent laboratory-based surveillance data will be required to determine how successful the 7-valent pneumococcal conjugate vaccine will be in reducing the incidence and improving the outcome of pneumococcal meningitis in the US. Conclusions To effectively treat bacterial meningitis, it is necessary to be familiar with recent epidemiologic changes. The widespread use of the H. influenzae type b conjugate vaccine dramatically decreased the incidence of meningitis caused by H. influenzae type b; S. pneumoniae is now the leading cause of bacterial meningitis in the US. Thus, S. pneumoniae must be considered the potential causative agent of bacterial meningitis in all age groups. In pneumococcal meningitis cases, familiarity with the local resistance patterns will provide guidance in the use of empiric antimicrobial therapy pending susceptibility testing of the microorganism. It is hoped that the recent licensure of the heptavalent pneumococcal conjugate vaccine will lead to a substantial decrease in the incidence of pneumococcal meningitis in the US. References and Recommended Reading Papers of particular interest, published recently, have been highlighted as: Of importance Of major importance 1. Carpenter RR, Petersdorf RG: The clinical spectrum of bacterial meningitis. Am J Med 1962, 33: Fraser DW, Henke CE, Feldman RA: Changing patterns of bacterial meningitis in Olmsted County, Minnesota, J Infect Dis 1973, 128: Fraser DW, Geil CC, Feldman RA: Bacterial meningitis in Bernalillo County, New Mexico: a comparison with three other American populations. Am J Epidemiol 1974, 100: Schlech WF III, Ward JI, Band JD, et al.: Bacterial meningitis in the United States, 1978 through The national bacterial meningitis surveillance study. JAMA 1985, 253: Wenger JD, Hightower AW, Facklam RR: the Bacterial Meningitis Study Group: Bacterial meningitis in the United States, 1986: report of a multistate surveillance study. J Infect Dis 1990, 162: Adams WG, Deaver KA, Cochi SL, et al.: Haemophilus influenzae Study Group: Decline of childhood Haemophilus influenzae type b disease in the Hib vaccine era. JAMA 1993, 269: Ahmad H, Chapnick EK: Conjugate polysaccharide vaccines. Infect Dis Clin North Am 1999, 13: This article discusses conjugate polysaccharide vaccines for Haemophilus influenzae, Streptococcus pneumoniae, and Neisseria meningitidis; availability of these vaccines may reduce the incidence of diseases caused by these microorganisms. 8. Centers for Disease Control and Prevention: FDA approval of use of Haemophilus b conjugate vaccine for infants. MMWR 1990, 339: American Academy of Pediatrics, Committee on Infectious Diseases: Recommended childhood immunization schedule United States, January-December Pediatrics 2000, 105: Robbins JB, Schneerson R, Anderson P, Smith DH: Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b. JAMA 1996, 276:
5 Changing Epidemiology of Bacterial Meningitis in the United States Short and Tunkel Van Alphen L, Spanjaard L, Van der Ende A, et al.: Effect of nationwide vaccination of 3-month-old infants in The Netherlands with conjugate Haemophilus influenzae type b vaccine: high efficacy and lack of herd immunity. J Pediatr 1997, 131: Mulholland K, Hilton S, Adegbola R, et al.: Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate for prevention of pneumonia and meningitis in Gambian infants. Lancet 1997, 349: Schuchat A, Robinson K, Wenger JD, et al.: Bacterial meningitis in the United States in N Engl J Med 1997, 337: This laboratory-based surveillance study of cases of bacterial meningitis in the United States 5 years after licensure of the Haemophilus influenzae type b conjugate vaccine shows that Streptococcus pneumoniae is now the most common etiologic agent of bacterial meningitis in the United States. 14. Campbell GD, Silberman R: Drug-resistant Streptococcus pneumoniae. Clin Infect Dis 1998, 26: This is a recent review of the mechanisms, risk factors, and approach to management in patients with antimicrobial-resistant S. pneumoniae infections. 15. Song JH, Lee NY, Ichiyama S, et al.: Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian network for surveillance of resistant pathogens (ANSORP) study. Clin Infect Dis 1999, 28: Ko AI, Reis JN, Coppola SJ, et al.: Clonally related penicillinnonsusceptible Streptococcus pneumoniae serotype 14 from cases of meningitis in Salvador, Brazil. Clin Infect Dis 2000, 30: Fung CP, Hu BS, Lee SC, et al.: Antimicrobial resistance of Streptococcus pneumoniae isolated in Taiwan: an islandwide surveillance study between 1996 and J Antimicrob Chemother 2000, 45: Hofmann J, Cetron MS, Farley MM, et al.: The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995, 333: This epidemiologic study of the prevalence of antimicrobial-resistant Streptococcus pneumoniae in Atlanta indicates that 25% of pneumococcal isolates are resistant to penicillin. 19. Klugman KP, Madhi SA: Emergence of drug resistance. Impact on bacterial meningitis. Infect Dis Clin North Am 1999, 13: Tunkel AR, Scheld WM: Acute meningitis. In Principles and Practice of Infectious Diseases edn 5. Edited by Mandell GL, Bennett JE, Dolin R. Philadelphia: Churchill-Livingstone; 1999: This chapter provides a recent discussion of the epidemiology, clinical presentation, diagnosis, and management of acute bacterial meningitis. It reviews specific recommendations for the approach to patients with antimicrobial-resistant meningeal pathogens. 21. Centers for Disease Control and Prevention: Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997, 46(RR-8): Rennels MB, Edwards KM, Keyserling HL, et al.: Safety and immunogenicity of heptavalent vaccine conjugated to CRM197 in United States infants. Pediatrics 1998, 101: Black S, Shinefield H, Fireman B, et al.:efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000, 19: These authors report the trial of the efficacy of the heptavalent pneumococcal conjugate vaccine, which demonstrates an efficacy of 97.4% in the prevention of invasive pneumococcal infections caused by the 7 serotypes of pneumococcus in the vaccine. 24. US Department of Health and Human Services: First pneumococcal vaccine approved for infants and toddlers. HHS News; February 17, Lieu TA, Ray GT, Black SB, et al.: Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 2000, 283: These authors project the efficacy and cost-effectiveness of the heptavalent pneumococcal conjugate vaccine in a hypothetical cohort of 3.8 million infants in the United States.
Haemophilus influenzae
Haemophilus influenzae type b Severe bacterial infection, particularly among infants During late 19th century believed to cause influenza Immunology and microbiology clarified in 1930s Haemophilus influenzae
More informationIncidence per 100,000
Streptococcus pneumoniae Surveillance Report 2005 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Department of Human Services Updated: March 2007 Background
More informationStreptococcus pneumoniae CDC
Streptococcus pneumoniae CDC Pneumococcal Disease Infection caused by the bacteria, Streptococcus pneumoniae» otitis media 20 million office visits (28-55% Strep)» pneumonia 175,000 cases annually» meningitis
More information...REPORTS... Epidemiology of Pneumococcal Disease/ Rationale for and Efficacy of PnC7
...REPORTS... Epidemiology of Pneumococcal Disease/ Rationale for and Efficacy of PnC7 Summary A Streptococcus pneumoniae Conjugate Vaccine Managed Care Advisory Panel was presented with information on
More informationPneumococcal vaccines
Pneumococcal vaccines Marco Aurélio Sáfadi, MD, PhD FCM da Santa Casa de São Paulo Challenges in establishing the baseline burden of disease, before implementing a vaccination program S. pneumoniae disease
More informationRecommended Childhood Immunization Schedu...ates, January - December 2000, NP Central
Recommended Childhood Immunization Schedule United States, January - December 2000 Vaccines 1 are listed under routinely recommended ages. Solid-colored bars indicate range of recommended ages for immunization.
More informationBacterial diseases caused by Streptoccus pneumoniae in children
Bacterial diseases caused by Streptoccus pneumoniae in children Bactermia 85% Bacterial pneumonia 66% Bacterial meningitis 50% Otitis media 40% Paranasal sinusitis 40% 0% 10% 20% 30% 40% 50% 60% 70% 80%
More informationPneumococcal Disease and Pneumococcal Vaccines
Pneumococcal Disease and Epidemiology and Prevention of - Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at
More informationStreptococcus Pneumoniae
Streptococcus Pneumoniae (Invasive Pneumococcal Disease) DISEASE REPORTABLE WITHIN 24 HOURS OF DIAGNOSIS Per N.J.A.C. 8:57, healthcare providers and administrators shall report by mail or by electronic
More informationThe New England Journal of Medicine BACTERIAL MENINGITIS IN THE UNITED STATES IN 1995
BACTERIAL MENINGITIS IN THE UNITED STATES IN 1995 ANNE SCHUCHAT, M.D., KATHERINE ROBINSON, M.P.H., JAY D. WENGER, M.D., LEE H. HARRISON, M.D., MONICA FARLEY, M.D., ARTHUR L. REINGOLD, M.D., LEWIS LEFKOWITZ,
More informationEXECUTIVE SUMMARY MEDICAL BACKGROUND
Pneumococcal Conjugate Vaccine for Young Children SHARON SELMAN*, DIANE HAYES*, LAWRENCE A. PERIN*, WINIFRED S. HAYES* *Hayes Inc.; School of Medicine and Biomedical Sciences, State University of New York
More informationPotential Impact of Conjugate Vaccine on the Incidence of Invasive Pneumococcal Disease among Children in Scotland
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2006, p. 1224 1228 Vol. 44, No. 4 0095-1137/06/$08.00 0 doi:10.1128/jcm.44.4.1224 1228.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved.
More informationCONJUGATE VACCINES A BREAKTHROUGH IN VACCINE DEVELOPMENT
CONJUGATE VACCINES A BREAKTHROUGH IN VACCINE DEVELOPMENT P Helena Mäkelä National Public Health Institute, Helsinki, Finland Abstract. The encapsulated bacteria Streptococcus pneumoniae (the pneumococcus),
More informationBacterial Meningitis in the United States,
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Bacterial Meningitis in the United States, 1998 2007 Michael C. Thigpen, M.D., Cynthia G. Whitney, M.D., M.P.H., Nancy E. Messonnier,
More informationPNEUMONIA : PROMISE FULFILLED? Regina Berba MD FPSMID
PNEUMONIA : PROMISE FULFILLED? Regina Berba MD FPSMID Objectives of Lecture Know the quality of current evidence based guidelines on immunization Appreciate the performance of pneumonia vaccines in terns
More informationVaccines for Primary Care Pneumococcal, Shingles, Pertussis
Vaccines for Primary Care Pneumococcal, Shingles, Pertussis Devang Patel, M.D. Assistant Professor Chief of Service, MICU ID Service University of Maryland School of Medicine Pneumococcal Vaccine Pneumococcal
More informationACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults
ACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults National Center for Immunization & Respiratory Diseases Respiratory Diseases Branch ACIP
More informationOf 142 cases where sex was known, 56 percent were male; of 127cases where race was known, 90 percent were white, 4 percent were
Group B Streptococcus Surveillance Report 2014 Oregon Active Bacterial Core Surveillance (ABCs) Center for Public Health Practice Updated: November 2015 Background The Active Bacterial Core surveillance
More information...REPORTS... Childhood Vaccination Against Pneumococcal Otitis Media and Pneumonia: An Analysis of Benefits and Costs
...REPORTS... Childhood Vaccination Against Pneumococcal Otitis Media and Pneumonia: An Analysis of Benefits and Costs Derek Weycker, PhD; Erin Richardson, BA; and Gerry Oster, PhD Abstract Objective:
More informationSource: Portland State University Population Research Center (
Neisseria meningitidis Surveillance Report 2009 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Health Authority Updated: June 2011 Background The Active
More informationAlberta Health and Wellness Public Health Notifiable Disease Management Guidelines August Pneumococcal Disease, Invasive (IPD)
August 2011 Pneumococcal Disease, Invasive (IPD) Revision Dates Case Definition Reporting Requirements Remainder of the Guideline (i.e., Etiology to References sections inclusive) Case Definition August
More informationHAEMOPHILUS INFLUENZAE INVASIVE DISEASE
23 Annual Morbidity Report HAEMOPHILUS INFLUENZAE INVASIVE DISEASE CRUDE DATA 35 Annual Incidence a LA County.37 California b. United States c.2 Age at Diagnosis Mean 4. years Median 36. years Range Birth
More informationPneumococcal vaccines. Safety & Efficacy. Prof. Rajesh Kumar, MD PGIMER School of Public Health Chandigarh
Pneumococcal vaccines Safety & Efficacy Prof. Rajesh Kumar, MD PGIMER School of Public Health Chandigarh Disclosure Slide X X I DO NOT have any significant or other financial relationships with industry
More informationIncidence per 100,
Group B Streptococcus Surveillance Report 2005 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Department of Human Services Updated: January 2007 Background
More informationPneumococcal infection is one of. Epidemiology of Pneumococcal Disease ...PRESENTATIONS... Based on a presentation by Chris Van Beneden, MD, MPH
...PRESENTATIONS... Epidemiology of Pneumococcal Disease Based on a presentation by Chris Van Beneden, MD, MPH Presentation Summary Pneumococcus is a leading cause of pneumonia and meningitis in the United
More informationRecommendations for Using Pneumococcal Vaccines among Adults
Recommendations for Using Pneumococcal Vaccines among Adults AI Collaborative Webinar February 2016 Tamara Pilishvili Respiratory Diseases Branch, CDC National Center for Immunization & Respiratory Diseases
More informationChapter 11: Pneumococcal Disease
Pneumococcal Disease: Chapter 11-1 Pneumococci can be found in the upper respiratory tract of 15% of well adults; in child care settings, up to 65% of children are colonized. Chapter 11: Pneumococcal Disease
More informationHaemophilus influenzae type B and Hib Vaccine Chapter 9
Haemophilus influenzae type B and Hib Vaccine Chapter 9 Haemophilus influenzae Aerobic gram-negative bacteria Polysaccharide capsule Six different serotypes (a-f) of polysaccharide capsule 95% of invasive
More informationInvasive Bacterial Disease
Invasive Bacterial Disease All Streptococcus pneumoniae Electronic Disease Surveillance System Division of Surveillance and Disease Control Infectious Disease Epidemiology Program : 304-558-5358 or 800-423-1271
More informationImmunization Update: New CDC Recommendations. Blaise L. Congeni M.D. 2012
Immunization Update: New CDC Recommendations Blaise L. Congeni M.D. 2012 Polysaccharide Vaccines Vaccine Hib capsule polysaccharide PRP (polyribose ribitol phosphate) Not protective in infants
More informationjournal of medicine The new england Decline in Invasive Pneumococcal Disease after the Introduction of Protein Polysaccharide Conjugate Vaccine
The new england journal of medicine established in 1812 may 1, 2003 vol. 348 no. 18 Decline in Invasive Pneumococcal Disease after the Introduction of Protein Polysaccharide Conjugate Vaccine Cynthia G.
More information9/12/2018. Pneumococcal Disease and Pneumococcal Vaccines. Streptococcus pneumoniae. Pneumococcal Disease. Adult Track. Gram-positive bacteria
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Pneumococcal Disease and Pneumococcal Vaccines Adult Track Chapter 17 Photographs and images included
More information3 rd dose. 3 rd or 4 th dose, see footnote 5. see footnote 13. for certain high-risk groups
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read
More informationAcute bacterial meningitis in Qatar ABSTRACT
Acute bacterial meningitis in Qatar Mahmoud F. Elsaid, MBBCH, CABP, Amina A. Flamerzi, MBBCH, CABP, Mohammed S. Bessisso, DCH, MD, Sittana S. Elshafie, MSc, FRCP (Path). ABSTRACT Objectives: To study the
More informationBCG vaccine and tuberculosis
PART 2: Vaccination for special risk groups 2.1 Vaccination for Aboriginal and Torres Strait Islander people Aboriginal and Torres Strait Islander people historically had a very high burden of infectious
More informationRecommendations for Using Pneumococcal Vaccines among Adults
Recommendations for Using Pneumococcal Vaccines among Adults AI Collaborative Webinar July 2017 Tamara Pilishvili Respiratory Diseases Branch, CDC National Center for Immunization & Respiratory Diseases
More information2013 Adult Immunization Update. David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle
2013 Adult Immunization Update David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Adult Immunization Update Pertussis Vaccine Influenza Vaccine Zoster
More informationEconomic Impact of a Pneumococcal Conjugate Vaccine in Managed Care
...PRESENTATIONS... Economic Impact of a Pneumococcal Conjugate Vaccine in Managed Care Based on a presentation by Tracy Lieu, MD, MPH* Presentation Summary Conjugate pneumococcal vaccines may soon allow
More informationImpact of vaccination on epidemiology in adults
Impact of vaccination on epidemiology in adults Jan Verhaegen 1. Data on prospective study on IPD in Belgium (2009-2011) 2. Evolution of capsular types of invasive isolates from adults after introduction
More information2016 Vaccine Preventable Disease Summary
2016 Vaccine Preventable Disease Summary 12251 James Street Holland, MI 49424 www.miottawa.org/healthdata Prepared October 2017 2016 Summary of Vaccine Preventable Diseases (VPDs) Reported to Ottawa County
More informationVaccines in Immunocompromised hosts
Vaccines in Immunocompromised hosts Carlos del Rio, MD Emory Center for AIDS Research October 2013 Immunocompromised hosts Number has increased rapidly in the past decades Broad term that encompasses different
More informationMethicillin-Resistant Staphylococcus aureus (MRSA) S urveillance Report 2008 Background Methods
Methicillin-Resistant Staphylococcus aureus (MRSA) Surveillance Report 2008 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Department of Human Services
More informationWhat DO the childhood immunization footnotes reveal? Questions and answers
What DO the childhood immunization footnotes reveal? Questions and answers Stanley E. Grogg, DO, FACOP, FAAP he Advisory Committee on Immunization Practices (ACIP) recommends the childhood vaccination
More informationNOTE: The above recommendations must be read along with the footnotes of this schedule.
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read
More informationPneumococcal Vaccines. What s right for your clients?
Pneumococcal Vaccines What s right for your clients? Vaccines Available - Pneumovax 23 A pneumococcal polysaccharide vaccine that includes 23 purified capsular polysaccharide antigens Vaccines Available
More informationEconomic Evaluation of a Universal Childhood Pneumococcal Conjugate Vaccination Strategy in Ireland
Volume 11 Number 5 2008 VALUE IN HEALTH Economic Evaluation of a Universal Childhood Pneumococcal Conjugate Vaccination Strategy in Ireland Lesley Tilson, BSc (Pharm), PhD, 1 Cara Usher, BSc, PhD, 1 Karina
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE
Last Updated: Version 4.4 NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Set: Immunization Set Measure ID#: Measure Information Form Collected For: CMS Voluntary Only The Joint Commission
More informationSurveillance of invasive pneumococcal infection in Belgium
Surveillance of invasive pneumococcal infection in Belgium National Reference Laboratory Start in 198 Laboratory Microbiology UH Leuven (prof. J. Vandepitte) Capsular type determination Antibiotic susceptibility
More informationInternational Journal of Infectious Diseases
International Journal of Infectious Diseases 14 (2010) e197 e209 Contents lists available at ScienceDirect International Journal of Infectious Diseases journal homepage: www.elsevier.com/locate/ijid Review
More informationTo view past issues, go to: The New 13-Valent Pneumococcal Conjugate Vaccine (PCV13)
From the Texas Department of State Health Services Immunization Branch The goal of the Vaccine Advisory is to disseminate, in a timely manner, practical information related to vaccines, vaccine-preventable
More informationRxVaccinate. Support. Objectives. Disclosures 7/8/2013. Pneumococcal Immunization Update
RxVaccinate Pneumococcal Immunization Update Stephan L. Foster, Pharm.D., FAPhA, FNAP Professor and Vice-Chair College of Pharmacy University of Tennessee Health Science Center, Memphis, TN Liaison Member,
More informationSplenectomy Vaccine Protocol PIDPIC
Splenectomy Vaccine Protocol PIDPIC 6.24.14 Rationale Spleen clears encapsulated bacteria and infected erythrocytes Serves as one of the largest lymphoid tissues where B cells are educated against encapsulated
More informationAcute Bacterial Meningitis : Causative Organisms, Clinical Characteristics and Prognosis
Acute Bacterial Meningitis : Causative Organisms, Clinical Characteristics and Prognosis Dong-Chul Park, M.D., Il-Saing Choi, M.D., Ji-Hoe Heo, M.D., Kyoung-Won Lee, M.D.* Departments of Neurology and
More informationBACTERIAL MENINGITIS: A FIVE YEAR ( ) RETROSPECTIVE STUDY AT UNIVERSITY MALAYA MEDICAL CENTer (UMMC), KUALA LUMPUR, MALAYSIA
BACTERIAL MENINGITIS: A FIVE YEAR (2001-2005) RETROSPECTIVE STUDY AT UNIVERSITY MALAYA MEDICAL CENTer (UMMC), KUALA LUMPUR, MALAYSIA H Erleena Nur, I Jamaiah, M Rohela and V Nissapatorn Department of Parasitology,
More informationGroup B Streptococcus
Group B Streptococcus (Invasive Disease) Infants Younger than 90 Days Old DISEASE REPORTABLE WITHIN 24 HOURS OF DIAGNOSIS Per N.J.A.C. 8:57, healthcare providers and administrators shall report by mail
More informationEffect of Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis
The new england journal of medicine original article Effect of Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis Heather E. Hsu, M.P.H., Kathleen A. Shutt, M.S., Matthew R. Moore, M.D., M.P.H.,
More informationcontinuing education for pharmacists
continuing education for pharmacists Pneumococcal Disease: Treatment and Prevention Volume XXXIV, No. 3 Donald L. Bennett, R.Ph., MBA, Clinical Assistant Professor, The Ohio State University College of
More informationBacterial meningitis in adults: Host and pathogen factors, treatment and outcome Heckenberg, S.G.B.
UvA-DARE (Digital Academic Repository) Bacterial meningitis in adults: Host and pathogen factors, treatment and outcome Heckenberg, S.G.B. Link to publication Citation for published version (APA): Heckenberg,
More informationThese slides are the property of the presenter. Do not duplicate without express written consent.
Cancer Survivorship Protecting Against Vaccine Preventable Diseases Heidi Loynes BSN, RN Immunization Nurse Educator Michigan Department of health and Human Services (MDHHS) loynesh@michigan.gov Are Vaccine-Preventable
More informationPneumococcal Pneumonia: Update on Therapy in the Era of Antibiotic Resistance
a of Antibiotic Resistance March 01, 2003 By Bernard Karnath, MD [1], Akua Agyeman, MD [2], and Albert Lai, MD [3] Sir William Osler once called pneumococcal pneumonia the captain of the men of death.
More informationAppendix A: Disease-Specific Chapters
Ministry of Health and Long-Term Care Infectious Diseases Protocol Appendix A: Disease-Specific Chapters Chapter: Haemophilus influenzae disease, all types, invasive Effective: May 2018 Haemophilus influenzae,
More informationImpact of pneumococcal conjugate vaccine: US experience Stephanie Schrag Centers for Disease Control and Prevention Atlanta, GA
Impact of pneumococcal conjugate vaccine: US experience Stephanie Schrag Centers for Disease Control and Prevention Atlanta, GA San Jose, Costa Rica, August 2007 Pneumococcal Conjugate Vaccine Introduction
More informationMulti-drug Resistant Serotype 19A Pneumococci in Toronto
TML Lab Rounds January 17, 2008 Multi-drug Resistant Serotype 19A Pneumococci in Toronto The Role of the Microbiology Lab Susan M. Poutanen, MD, MPH, FRCPC Microbiologist/ID Consultant, TML/MSH Assistant
More informationImmunizations (Guideline Intervals Using The Rule of Six for Vaccines Birth to Six Years)
Immunizations (Guideline Intervals Using The Rule of Six for Vaccines Birth to Six Years) Guideline developed by Shelly Baldwin, MD, in collaboration with the ANGELS Team. Last reviewed by Shelly Baldwin,
More informationUPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES
DISCLOSURES UPDATE ON IMMUNIZATION GUIDELINES AND PRACTICES Nothing to disclose Kylie Mueller, Pharm.D., BCPS Clinical Specialist, Infectious Diseases Spartanburg Regional Medical Center LEARNING OBJECTIVES
More informationFever Interval before Diagnosis, Prior Antibiotic Treatment, and Clinical Outcome for Young Children with Bacterial Meningitis
MAJOR ARTICLE Fever Interval before Diagnosis, Prior Antibiotic Treatment, and Clinical Outcome for Young Children with Bacterial Meningitis Bema K. Bonsu 1 and Marvin B. Harper 2 1 Department of Medicine,
More informationThe Role of the Pharmacist in Pneumococcal Vaccination
The Role of the Pharmacist in Pneumococcal Vaccination The Role of the Pharmacist in Pneumococcal Vaccination Miranda Wilhelm, PharmD Clinical Associate Professor Department of Pharmacy Practice Southern
More informationORIGINAL ARTICLE /j x
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.00869.x Invasive Streptococcus pneumoniae from Portugal: implications for vaccination and antimicrobial therapy I. Serrano, M. Ramirez, the Portuguese Surveillance
More informationHaemophilus influenzae Surveillance Report 2012 Oregon Active Bacterial Core Surveillance (ABCs) Center for Public Health Practice Updated: July 2014
Haemophilus influenzae Surveillance Report 2012 Oregon Active Bacterial Core Surveillance (ABCs) Center for Public Health Practice Updated: July 2014 Background The Active Bacterial Core surveillance (ABCs)
More informationS. Michael Marcy Memorial Lecture
S. Michael Marcy Memorial Lecture Lessons Learned from Making Vaccine Recommendations Larry K. Pickering, MD, FAAP April 16, 2016 Los Angeles, CA FINANCIAL DISCLOSURE: Larry K. Pickering, M.D., F.A.A.P.
More informationVaccinations for Adults
Case: Vaccinations for Adults Lisa Winston, MD University of California, San Francisco San Francisco General Hospital A 30-year old healthy woman comes for a routine visit. She is recently married and
More informationEPIREVIEW INVASIVE PNEUMOCOCCAL DISEASE, NSW, 2002
EPIREVIEW INVASIVE PNEUMOCOCCAL DISEASE, NSW, 2002 Robyn Gilmour Communicable Diseases Branch NSW Department of Health BACKGROUND Infection with the bacterium Streptococcus pneumoniae is a major cause
More informationGlobal Evolution of the Pneumococcus and the Impact of Vaccination Keith P. Klugman
Global Evolution of the Pneumococcus and the Impact of Vaccination Keith P. Klugman Department of Global Health, Rollins School of Public Health and Division of Infectious Diseases, School of Medicine
More informationImpact of Universal Infant Immunization with Pneumococcal (Streptococcus pneumonia) Conjugate Vaccines in Alaska
Pacific University CommonKnowledge School of Physician Assistant Studies Theses, Dissertations and Capstone Projects 8-2008 Impact of Universal Infant Immunization with Pneumococcal (Streptococcus pneumonia)
More informationCNS Infections. GBS Streptococcus agalactiae. Meningitis - Neonate
CNS Infections GBS Streptococcus agalactiae Bacterial meningitis - Pathophysiology - general Specific organisms - Age Hosts Treatment/Prevention Distinguish from viral disease Common commensal flora childbearing
More informationPneumococcal conjugate vaccine primes for polysaccharide inducible IgG2 antibody response in children with recurrent Otitis Media
Pneumococcal conjugate primes for IgG2 response Chapter 5a Pneumococcal conjugate vaccine primes for polysaccharide inducible IgG2 antibody response in children with recurrent Otitis Media Mijke A. Breukels,
More information(ACIP) 2018:28:69-76 DOI: /ICJ _28(2) (07)
69 1 2 1 2 (ACIP) B 2018:28:69-76 E 106 1 15 107 3 14 123 (07) 7317123 DOI: 10.6526/ICJ.201804_28(2).0003 107 4 70 [1] (Tdap) B E (estradiol) T (type 2 helper T-cell, Th2) T (type 1 helper T-cell, Th1)
More informationInvasive Pneumococcal Disease in Kanti Children s Hospital, Nepal, as Observed by the South Asian Pneumococcal Alliance Network
SUPPLEMENT ARTICLE Invasive Pneumococcal Disease in Kanti Children s Hospital, Nepal, as Observed by the South Asian Pneumococcal Alliance Network A. S. Shah, 1 M. Deloria Knoll, 2 P. R. Sharma, 1 J. C.
More informationState of Hong Kong Children
HK J Paediatr (new series) 2001;6:127-132 State of Hong Children Proceedings of The First Current Topic in Infectious Diseases: Consensus Meeting on Conjugate Vaccines of the Center of Infection, Faculty
More informationAcute Bacterial Meningitis in Infants and Children Epidemiology and Management
REVIEW ARTICLE Pediatr Drugs 2011; 13 (6): 385-400 1174-5878/11/0006-0385/$49.95/0 ª 2011 Adis Data Information BV. All rights reserved. Acute Bacterial Meningitis in Infants and Children Epidemiology
More informationOREGON PUBLIC HEALTH, DHS IMMUNIZATION PROTOCOL FOR PHARMACISTS. PNEUMOCOCCAL POLYSACCHARIDE VACCINE 23-Valent Vaccine
OREGON PUBLIC HEALTH, DHS IMMUNIZATION PROTOCOL FOR PHARMACISTS PNEUMOCOCCAL POLYSACCHARIDE VACCINE 23-Valent Vaccine Revisions as of 2/24/10 Pneumovax 23 should not be given concurrently with Zostavax
More informationChanging Epidemiology of Invasive Pneumococcal Disease Among Older Adults in the Era of Pediatric Pneumococcal Conjugate Vaccine
ORIGINAL CONTRIBUTION Changing Epidemiology of Invasive Pneumococcal Disease Among Older Adults in the Era of Pediatric Pneumococcal Conjugate Vaccine Catherine A. Lexau, PhD, MPH Ruth Lynfield, MD Richard
More informationCurrent Status of PCV Use and WHO Recommendations
Current Status of PCV Use and WHO Recommendations SAGE 18 October 2017 Kate O Brien, MD MPH 1 Pneumonia remains a major cause of child deaths LMIC LMIC Pneumonia HIC HIC Pneumonia ~16% ~5% 2015 Black,
More informationCalender of Pediatric Immunizations in Brazil
Calender of Pediatric Immunizations in Brazil Otávio Augusto Leite Cintra 1. Background Immunization or vaccination is one of the more effective actions for disease prevention in the individual and community
More informationPneumococcal Vaccine Effectiveness. Steven Black, MD Center for Global Health Cincinnati Children s s Hospital Cincinnati, Ohio USA
Pneumococcal Vaccine Effectiveness Steven Black, MD Center for Global Health Cincinnati Children s s Hospital Cincinnati, Ohio USA Overview Possible effectiveness outcomes for pneumococcal vaccines Pre-licensure
More informationGUIDELINE FOR THE MANAGEMENT OF MENINGITIS. All children with suspected or confirmed meningitis
GUIDELINE FOR THE MANAGEMENT OF MENINGITIS Reference: Mennigitis Version No: 1 Applicable to All children with suspected or confirmed meningitis Classification of document: Area for Circulation: Author:
More informationImmunization Guidelines for the Use of State Supplied Vaccine April 18, 2013
DTaP / DT DTaP/IPV/Hep B Combination (Pediarix ) Children from 6 weeks of age up to the 7 th birthday Children from 2 months of age up to the 7th birthday: Indicated for the primary doses of DTaP, IPV,
More informationRoutine Adult Immunization: American College of Preventive Medicine Practice Policy Statement, updated 2002
Routine Adult Immunization: American College of Preventive Medicine Practice Policy Statement, updated 2002 Ann R. Fingar, MD, MPH, and Byron J. Francis, MD, MPH Burden of suffering Vaccines are available
More information2015 Vaccine Preventable Disease Summary
2015 Vaccine Preventable Disease Summary 12251 James Street Holland, MI 49424 www.miottawa.org/healthdata Prepared April 2016 2015 Summary of Vaccine Preventable Diseases (VPD) Reported to Ottawa County
More informationHaemophilus influenzae and its invisibility cloak. Anna Strain Virology Supervisor/VPD Reference Center Coordinator June 5, 2018
Haemophilus influenzae and its invisibility cloak Anna Strain Virology Supervisor/VPD Reference Center Coordinator June 5, 2018 Haemophilus influenzae Gram negative aerobic coccobacilli Pfeiffer s Bacillus-
More informationAndrew Kroger, MD, MPH National Center for Immunization and Respiratory Diseases MCH & Immunization Conference Anchorage, AK September 28, 2010
2010 Immunization Update Andrew Kroger, MD, MPH National Center for Immunization and Respiratory Diseases MCH & Immunization Conference Anchorage, AK September 28, 2010 Disclosures No financial conflict
More informationPneumococcal 13-valent Conjugate Vaccine Biological Page
Pneumococcal 13-valent Conjugate Vaccine Biological Page Section 7: Biological Product Information Standard #: 07.291 Created by: Province-wide Immunization Program Standards and Quality Approved by: Province-wide
More informationImpacto de la vacuna conjugada en EUA
Impacto de la vacuna conjugada en EUA Richard Facklam, PhD, Distinguished Consultant, Retired, Centers for Disease Control and Prevention Atlanta, GA Bogotá, Colombia, February 2008 Pneumococcal Conjugate
More informationDisclosure Statement. Encapsulated Bacteria. Functions of the Spleen 10/25/2017. Pharmacist Learning Objectives
Pharmacist Learning Objectives No Spleen? No Problem. A Review of Vaccinations Indicated for the Asplenic Patient SCSHP Fall Meeting October 26, 2017 Explain the rationale for vaccinations in Select the
More informationB 型嗜血感冒桿菌感染及 其疫苗 衛生署疾病管制局 中區傳染病防治醫療網 王任賢指揮官
B 型嗜血感冒桿菌感染及 其疫苗 衛生署疾病管制局 中區傳染病防治醫療網 王任賢指揮官 Haemophilus influenzae type b Severe bacterial infection, particularly among infants During late 19th century believed to cause influenza Immunology and microbiology
More informationDeaths/yr Efficacy Use Prev Deaths/yr. Influenza 36,000 70% 60% 18,000. Pneumonia 40,000 60% 40% 20,000 HBV 6,000 90% 30% 4,000
Tetanus, Diptheria, Pertussis,! Measles, Mumps, Rubella, Varicella, HPV, Polio Meningococcus, Pneumococcus,! Influenza, Hepatitis B, Hepatitis A,! H influenza, Rabies, Typhoid,! Yellow Fever, Japanese
More informationORIGINAL ARTICLES. Pneumococcal conjugate vaccine a health priority. The burden of pneumococcal pneumonia. Heather J Zar, Shabir A Madhi
Pneumococcal conjugate vaccine a health priority Heather J Zar, Shabir A Madhi Pneumonia is a major cause of childhood mortality and morbidity. Streptococcus pneumoniae is the most important bacterial
More informationACIP Meeting Update, New Recommendations and Pending Influenza Season
ACIP Meeting Update, New Recommendations and Pending Influenza Season February 17 th 2011 www.immunizetexas.com ACIP Upcoming Agenda and New Recommendations ACIP (February 23-24 th 2011) Topics for meeting
More information41 Pneumococcal Disease
41 Pneumococcal Disease Epidemiology and Prevention Abstract: Streptococcus pneumonie is a major cause of morbidity and mortality in very young, high-risk adults and elderly population. It kills almost
More information